BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...preventing the nuclear localization of proteins essential for DNA replication and mismatch repair, such as RFC5...
...Phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase PD-1 (PDCD1; CD279) - Programmed cell death 1 RFC5 - Replication factor C subunit 5...
BioCentury | Mar 8, 2010
Emerging Company Profile

Virdante: Superpowering Sialylation

Intravenous immune globulin products provide symptomatic relief for autoimmune and inflammatory conditions when given at high doses. Virdante Pharmaceuticals Inc. is developing an IVIG product that is 10 times more potent in preclinical models, which...
BioCentury | Sep 16, 2002
Tools & Techniques

Adjuvant blocking & tackling

The challenge for many vaccines is to maximize the CD8 T cell response to disease-specific antigens in order to control or eradicate chronic viral diseases or cancer. To get the most throw weight, many companies...
BioCentury | Sep 16, 2002
Company News

Immunex, Wyeth other research news

Researchers published in the Proceedings of the National Academy of Sciences that CD40L, GM-CSF and IL-13R-Fc treatment synergistically enhance vaccine-mediated CD8 T cell induction. In mice, treatment with CD40L and GM-CSF enhanced vaccine-stimulated specific T...
BioCentury | Jul 17, 1995
Company News

Sepragen, Yuasa Trading Co. Ltd. deal

Yuasa (Tokyo) will exclusively distribute SPGNU's bioseparations products in Japan. SPGNU's products use radial flow chromatography (RFC), a technology that was developed to overcome flow rate and pressure problems that can occur using traditional axial...
Items per page:
1 - 5 of 5